ProPhase Labs, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
ProPhase Labs, Inc. (PRPH) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value of $0 as of 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue · last filed 2026-06-01
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $0.00.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $0.00.
- 2025-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $0.00.
- 2025-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-06-01 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-19 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-20 |
| 2024-12-31 | $0.00 10-K · filed 2025-04-01 |
| 2024-09-30 | $23.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $563.00K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $2.29M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $693.00K 10-K · filed 2024-03-29 |
| 2019-06-30 | $1.92M 10-Q · filed 2019-08-12 |
| 2019-03-31 | $1.08M 10-Q · filed 2019-05-14 |
| 2018-12-31 | $777.00K 10-K · filed 2019-03-26 |
| 2018-06-30 | $150.00K 10-Q · filed 2019-08-12 |
| 2016-12-31 | $1.20M 10-K · filed 2017-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |